1530P Durvalumab (D) + platinum-etoposide (EP) in first-line extensive-stage SCLC (ES SCLC): Effect of age and platinum agent on outcomes in CASPIAN
| Autor: | Reinmuth, N., Goldman, J.W., Chen, Y., Hotta, K., Statsenko, G., Hochmair, M.J., Özgüroğlu, M., Ji, J.H., Garassino, M.C., Poltoratskiy, A., Verderame, F., Havel, L., Bondarenko, I., Losonczy, G., Conev, N.V., Mann, H., Chugh, P., Dalvi, T.B., Paz-Ares, L. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S1245-S1246 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|